Navigation Links
Excalibur International Marine (49% Owned by EFT BioTech Holdings) Completes Inaugural Passenger Crossing of Taiwan Strait
Date:6/30/2009

CITY OF INDUSTRY, Calif. and HONG KONG, June 30 /PRNewswire-FirstCall/ -- EFT BioTech Holdings, Inc. (Pink Sheets: EFTB), announced today that Excalibur's Ocean LaLa has successfully completed its inaugural Taiwan Strait passenger voyage which has been highlighted in multiple news articles and internet news sites, including the Taiwan Sun, and the Qatar Tribune. The article states:

"A Taiwan company launched a cruise service with China on Sunday, making it the first such cross-strait service in 60 years.

"With a band playing and dragon dance performing on shore, the 2,292-tonne Ocean LaLa set sail from the Taichung Harbour for Xiamen, China, carrying 179 passengers and 23 crew.

"The voyage across the Taiwan Strait takes only four-and-a-half-hours, but it took Taiwan and China 60 years to ease tension and for Taipei to agree to lift the ban on sea links with the mainland."

The Excalibur International Marine Corp, operator of the cruise service, said that in the initial stage, the Taichung-Xianmen cruise is an irregular service chartered by travel agencies.

"Eventually it will become a regular cruise service going not only to Xiamen, but also to other Chinese ports like Fuzhou and Shanghai," said Han Chih-yang, Excalibur's deputy.

"We are full of confidence for the future of cross-strait tourism, so we are seeking to buy two larger ships for launching regular cross-strait service," he said.

Jack Qin, the President and CEO of EFT BioTech Holdings, stated, "We are excited to be recognized by the world press and this article shows that people are truly interested in this much needed passenger and cargo service."

About EFT BioTech Holdings, Inc.

EFT BioTech Holdings, Inc. is a Nevada holding company which conducts its business through its wholly-owned subsidiary, EFT Bio
'/>"/>

SOURCE EFT BioTech Holdings, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Excalibur - Transforming Biotech Deals can Still be Achieved
2. Excalibur Celebrates PIramed Sale With Substantial Cash Return to Investors
3. Galichia Heart Hospital Partners with Mobile Surgery International to Develop Wichita-based Center of Excellence with Global Convenience(TM)
4. International Products Corp.s Lab Offers Filter Membrane Compatibility and Studies
5. Cord Blood America Continues International Expansion
6. PAREXEL International to Present at the Wachovia Equity Conference
7. BioEnergy International, LLC Announces Formation of Myriant Technologies LLC
8. Biostar Pharmaceuticals, Inc. Retains HC International, Inc. to Implement Investor Relations Program
9. NeoStem, Inc. Appoints Financial Expert with Broad International Experience to the Board of Directors and to Serve as Chairman of the Companys Audit Committee
10. Yongye Biotechnology International Receives License to Manufacture Products
11. Cynvec to Present at the 11th Annual Shanghai International Forum on Biotechnology and Pharmaceutical Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... (PRWEB) May 29, 2015 Results from ... talimogene laherparepvec and its ability to reduce the size ... have been published in the Journal of Clinical Oncology. ... with stages IIIB, IIIC and IV melanoma, a potentially ... the study was to evaluate the safety and efficacy ...
(Date:5/28/2015)... , May 28, 2015 ... has announced the addition of Jain PharmaBiotech,s ... Technologies, Markets, and Companies" to their ... This report deals with therapeutic ... at improving patient care by monitoring drug ...
(Date:5/28/2015)... 2015 Research and Markets( http://www.researchandmarkets.com/research/l9dqwt/animal_genetics ) has ... by Products, by Testing services - Global Forecast to ... global animal genetics market is estimated to be worth ... CAGR of 8-9% during the forecast period of 2014 ... by increasing animal protein consumption, increasing adoption of advanced ...
(Date:5/28/2015)... N.J. , May 28, 2015 Celsion ... that it has received commitments from two institutional healthcare ... of the Company,s common stock in an at-the-market registered ... to purchase common stock. The Company entered ... to which the Company agreed to sell an aggregate ...
Breaking Biology Technology:Study Published in Journal of Clinical Oncology Reports Talimogene Laherparepvec Improvesdurable Responses in Patients with Advanced Melanoma 2Global Therapeutic Drug Monitoring Market 2015-2024 2Global Animal Genetics (Canine, Equine, Poultry, Porcine, Bovine, and Genetic Material) Market 2015 - Global Forecast to 2020 2Celsion Corporation Announces $8 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $8 Million At-The-Market Registered Direct Offering 3
... a leader in forest tree improvement technologies, ... that are utilizing technology in-licensed from Senesco Technologies, Inc. ... companies had previously announced that trees that incorporate Senesco ... field trials. , , Selected trees from ...
... , , Data published in July 7, ... Academy of Sciences, , , QUEBEC CITY, July 7 ... TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy ... journal, Proceedings of the National Academy of Sciences (PNAS), of ...
... , THE WOODLANDS, Texas, July 7 Lexicon ... biopharmaceutical company focused on discovering and developing breakthrough treatments for ... 2 clinical trial of LX1032 , the ... carcinoid syndrome . LX1032 is designed ...
Cached Biology Technology:ArborGen and Senesco Announce Wood Quality Results 2ArborGen and Senesco Announce Wood Quality Results 3ArborGen and Senesco Announce Wood Quality Results 4AEterna Zentaris: New Data Published on its Ghrelin Antagonist Compound, AEZS-123 (JMV2959), Supports its Use in Alcohol Addiction 2AEterna Zentaris: New Data Published on its Ghrelin Antagonist Compound, AEZS-123 (JMV2959), Supports its Use in Alcohol Addiction 3AEterna Zentaris: New Data Published on its Ghrelin Antagonist Compound, AEZS-123 (JMV2959), Supports its Use in Alcohol Addiction 4Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome 2Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome 3Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome 4
(Date:5/26/2015)... DUBLIN , May 26, 2015 ... has announced the addition of the "Saudi ... report to their offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... Saudi Arabia is projected to grow ... This high growth is attributed to the surging ...
(Date:5/22/2015)... DALLAS , May 22, 2015 ... Recognition Market by Solution (2D, 3D, Thermal, Emotion, Forensic), by ... End User (Government and Utilities, Consumer and Home) - ... Market to grow from $2.77 Billion in 2015 to ... Browse 79 market data Tables and ...
(Date:5/20/2015)... DUBLIN , May 20, 2015 ... Markets ( http://www.researchandmarkets.com/research/h8t4x6/5year ) has announced the ... of the Global Iris Recognition Market" ... http://photos.prnewswire.com/prnh/20130307/600769) , ,This research service analyses ... across the government and commercial sectors, ...
Breaking Biology News(10 mins):Saudi Arabia Biometric Systems Market Forecast and Opportunities, 2020 with Morpho Safran, ZK Technlogy, and Suprema Dominating 2Facial Recognition Market Worth $6.19 Billion by 2020 2Facial Recognition Market Worth $6.19 Billion by 2020 3Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2
... F.L. MARCH 27, 2009 The founder of a ... genetic tests in making medical decisions is the 2009 ... for lifetime achievement in the field of genetic sciences. ... the University of Washington School of Medicine in Seattle, ...
... Scripps Research Institute has obtained the first glimpse of a ... cells. The protein, called P-glycoprotein or P-gp for short, is ... chemotherapy drugs. Understanding its structure may help scientists design more ... March 27, 2009, issue of the journal Science . ...
... new drug developed at the University of California, Davis ... II of human clinical trials to evaluate its efficacy. ... (s-EH) inhibitor, is "a first-in-class drug which may treat ... entomologist Bruce Hammock, who with UC Berkeley cell biologist ...
Cached Biology News:Roberta A. Pagon receives lifetime award in genetics from March of Dimes 2Scripps scientists find structure of a protein that makes cancer cells resistant to chemotherapy 2Scripps scientists find structure of a protein that makes cancer cells resistant to chemotherapy 3UC Davis bench-to-bedside research: Promising treatment in clinical trials 2UC Davis bench-to-bedside research: Promising treatment in clinical trials 3UC Davis bench-to-bedside research: Promising treatment in clinical trials 4UC Davis bench-to-bedside research: Promising treatment in clinical trials 5
Human GCP-2 is a member of the CXC family of chemokines. It also promotes neutrophil chemotaxis and deganulation. GF063 is an 8.0 kDa protein containing 73 amino acid residues....
... Buffer contains a precipitant to ensure that the ... dye to allow the user to follow the ... ReddyRun™: ABgene ® s proprietary mixture of ... buffer composition used in ReddyRun™ molecular weight markers. ...
... number is a new ... easily match Cornings product ... availability yet, please order ... number (Z71,381-3) or contact ...
Excellent safety and durability., Remote control can be easily operated in your hand., Constant voltage control with 2 sets of terminals., Precise and durable circuit design. ...
Biology Products: